Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeogenNEOG -2.30%65 Days Payable is 59.91 as of May. 2026, which is 61% above its 10-year median of 37.18. GuruFocus rates NEOG with a GF Score™ of 65/100 and a GF Value™ of $11.17 (Fairly Valued). The stock has 5 warning signs investors should review. Among 793 Medical Devices & Instruments companies, Neogen ranks worse than 59.27% on this metric.
Neogen's average Accounts Payable for the
three
months ended in May. 2026 was $77.2 Mil. Neogen's Cost of Goods Sold for the
three
months ended in May. 2026 was $117.5 Mil.
Hence, Neogen's Days Payable for the
three
months ended in May. 2026 was 59.91.
The historical rank and industry rank for Neogen's Days Payable or its related term are showing as below:
NEOG'
s Days Payable Range Over the Past 10 Years
Min: 30.88 Med: 37.18 Max: 63.33
Current: 59.03
During the past 13 years, Neogen's highest Days Payable was 63.33. The lowest was 30.88. And the median was 37.18.
NEOG's Days Payable is ranked worse than 59.27% of 793
companies
in the Medical Devices & Instruments industry
Industry Median: 68.47
vs NEOG: 59.03
Neogen's Days Payable
increased
from May. 2025 (52.25) to May. 2026 (59.91).
It may suggest that Neogendelayed paying its suppliers.
The historical data trend for Neogen's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Neogen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's Days Payable distribution charts can be found below:
* The bar in red indicates where Neogen's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Neogen's Days Payable for the fiscal year that ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (NEOG) has a Days Payable of 59.91 as of May. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neogen and its competitors. This is 61% above median its historical median of 37.18. Over the past decade, Neogen's Days Payable has ranged from 30.88 to 63.33. According to the industry distribution chart, Neogen ranks #470 out of 793 companies in the Medical Devices & Instruments industry, placing it in the top 59.3%.
Is Neogen's Days Payable too high?
Neogen's current Days Payable of 59.91 is 61% above median its 10-year median of 37.18. Over the past 10 years, this metric has ranged from a low of 30.88 to a high of 63.33. The Medical Devices & Instruments industry median Days Payable is 68.47. Neogen's value of 59.91 is 12.5% below this industry median. Based on the distribution chart, Neogen ranks #470 out of 793 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Neogen has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Days Payable compare to NVCR and AXGN?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #470 out of 793 companies for Days Payable. This places Neogen in the lower half of its industry. The industry median Days Payable is 68.47. Neogen's value of 59.91 is 12.5% below this benchmark. Historically, Neogen's own Days Payable has ranged from 30.88 to 63.33 over the past decade. While the company's 10-year median is 37.18 vs. the industry median of 68.47, Neogen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.47, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neogen's current Days Payable of 59.91 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neogen and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neogen's current Days Payable is 59.91, which is 61% above median its own 10-year median of 37.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (NEOG) is currently considered Fairly Valued. The stock's GF Value™ is $11.17, compared to a current price of $11.87 — trading 6.3% above its estimated fair value. The current Days Payable is 59.91, which is 61% above median its 10-year median of 37.18 and 12.5% below the Medical Devices & Instruments industry median of 68.47. Neogen's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Neogen (NEOG), the current Days Payable is 59.91 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (NEOG) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be overvalued.
The current stock price of $11.87 is trading 6.3% above its estimated GF Value™ of $11.17.
GuruFocus considers Neogen to be Fairly Valued.
Key valuation signals for NEOG:
Days Payable: 59.91 (61% above median its 10-year median of 37.18)
GF Value™: $11.17 vs. price of $11.87 (6.3% above fair value)
Industry Position: 12.5% below the Medical Devices & Instruments median (#470 of 793)
No single metric tells the full story. See the NEOG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
65GF Score
Get the complete analysis for NEOG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEOG has been successfully added to your 
